Ovarian Carcinoma heterogeneity as demonstrated by DNA ploidy
1993
Background. In ovarian carcinoma, DNA ploidy measured by flow cytometric (FCM) analysis is an independent prognostic factor. However, limited sampling may underestimate the extent of ploidy variation (i.e., heterogeneity). Uncovering these hidden populations may explain poor outcomes in patients with ostensibly favorable ploidy patterns. The authors examined ploidy in a mean of 6.4 tumor samples per patient to better assess the occurrence of heterogeneity
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
11
References
27
Citations
NaN
KQI